Date: 2014-12-19
Type of information: Licensing agreement
Compound: ONO-4059
Company: Gilead Sciences (USA - CA) Ono Pharmaceutical (Japan)
Therapeutic area: Cancer -Oncology
Type agreement: licensing development commercialisation
Action mechanism: ONO-4059 is a selective, once-daily, oral inhibitor of Bruton’s tyrosine kinase (BTK) which has been shown to play a role in the survival and proliferation of malignant B-cells.
Disease: B-cell malignancies and other diseases
Details: * On December 19, 2014, Ono Pharmaceutical and Gilead Sciences announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO’s oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases. The companies will collaborate jointly on global development of ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations (ASEAN) countries, where ONO retains development and commercialization rights. Ono and Gilead plan to develop ONO-4059 for the treatment of B-cell malignancies and other diseases as a monotherapy and in combination with approved and investigational agents, including combinations with kinase inhibitors in Gilead’s portfolio.
Financial terms: Under the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones.
Latest news:
